MEPDF vs SHPMY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MEPDF is a Hold and SHPMY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MEPDF’s FA Score shows that 0 FA rating(s) are green whileSHPMY’s FA Score has 0 green FA rating(s).
- MEPDF’s FA Score: 0 green, 5 red.
- SHPMY’s FA Score: 0 green, 5 red.
Price Growth
MEPDF (@Medical Distributors) experienced а 0.00% price change this week, while SHPMY (@Medical Distributors) price change was -11.07% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was +1.36%. For the same industry, the average monthly price growth was -8.72%, and the average quarterly price growth was -11.89%.
Industries' Descriptions
@Medical Distributors (+1.36% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
| MEPDF | SHPMY | MEPDF / SHPMY | |
| Capitalization | 3.69B | 9.5B | 39% |
| EBITDA | 74B | 11.1B | 667% |
| Gain YTD | 26.873 | -18.056 | -149% |
| P/E Ratio | 12.29 | 8.39 | 146% |
| Revenue | 3.35T | 241B | 1,390% |
| Total Cash | 252B | N/A | - |
| Total Debt | 30B | N/A | - |
MEPDF | SHPMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 44 | 34 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 41 | 100 | |
SMR RATING 1..100 | 41 | 81 | |
PRICE GROWTH RATING 1..100 | 39 | 61 | |
P/E GROWTH RATING 1..100 | 73 | 67 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SHPMY's Valuation (34) in the null industry is somewhat better than the same rating for MEPDF (91). This means that SHPMY’s stock grew somewhat faster than MEPDF’s over the last 12 months.
MEPDF's Profit vs Risk Rating (41) in the null industry is somewhat better than the same rating for SHPMY (100). This means that MEPDF’s stock grew somewhat faster than SHPMY’s over the last 12 months.
MEPDF's SMR Rating (41) in the null industry is somewhat better than the same rating for SHPMY (81). This means that MEPDF’s stock grew somewhat faster than SHPMY’s over the last 12 months.
MEPDF's Price Growth Rating (39) in the null industry is in the same range as SHPMY (61). This means that MEPDF’s stock grew similarly to SHPMY’s over the last 12 months.
SHPMY's P/E Growth Rating (67) in the null industry is in the same range as MEPDF (73). This means that SHPMY’s stock grew similarly to MEPDF’s over the last 12 months.
| RSI ODDS (%) |
| Stochastic ODDS (%) |
| Momentum ODDS (%) |
| MACD ODDS (%) |
| TrendWeek ODDS (%) |
| TrendMonth ODDS (%) |
| Advances ODDS (%) |
| Declines ODDS (%) |
| BollingerBands ODDS (%) |
| Aroon ODDS (%) |
MEPDF and
Correlation & Price change
A.I.dvisor tells us that MEPDF and COSM have been poorly correlated (+12% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MEPDF and COSM's prices will move in lockstep.
| Ticker / NAME | Correlation To MEPDF | 1D Price Change % | ||
|---|---|---|---|---|
| MEPDF | 100% | N/A | ||
| COSM - MEPDF | 12% Poorly correlated | +1.70% | ||
| MAHLY - MEPDF | 9% Poorly correlated | -0.84% | ||
| SHPMF - MEPDF | 2% Poorly correlated | N/A | ||
| PDRX - MEPDF | 0% Poorly correlated | N/A | ||
| ARRJF - MEPDF | 0% Poorly correlated | N/A | ||
More | ||||
SHPMY and
Correlation & Price change
A.I.dvisor tells us that SHPMY and PDRX have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SHPMY and PDRX's prices will move in lockstep.
| Ticker / NAME | Correlation To SHPMY | 1D Price Change % | ||
|---|---|---|---|---|
| SHPMY | 100% | N/A | ||
| PDRX - SHPMY | 8% Poorly correlated | N/A | ||
| ZYXI - SHPMY | 5% Poorly correlated | -0.23% | ||
| NSVGF - SHPMY | 4% Poorly correlated | N/A | ||
| SHTDF - SHPMY | 3% Poorly correlated | N/A | ||
| MEPDF - SHPMY | -3% Poorly correlated | N/A | ||
More | ||||